Skip to NavigationSkip to content

AC Immune

Working Life Interview: Dr Andrea Pfeifer, Co-Founder and CEO, AC Immune

Published on 11/02/20 at 12:49pm

What originally set you off on your career path? Was the plan always to go into the pharma and biotech industry?

Roche pulls plug on Alzheimer's drug after Phase 3 failure

Roche has announced that it is to terminate two Phase 3 studies investigating the efficacy of its anti-beta-amyloid molecule crenezumab in the treatment of early sporadic Alzheimer’s disease (AD), after it became apparent that the drug was unlikely to meet its primary endpoint.

The decision was taken when a pre-planned interim analysis undertaken by an Independent Data Monitoring Committee determined that crenezumab would not generate an improvement from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score.

World’s first Alzheimer’s vaccine trial begins

AC Immune, a privately-held biotech based in Switzerland, has launched the world’s first trial of a vaccine against a protein believed to cause Alzheimer’s disease.

The drug, known as the ACI-35 vaccine, is designed to stimulate the body’s immune system to produce antibodies which target the tau protein.

This protein is believed to form in the brain and create ‘tangles’, and is one of two main theories on the causes of Alzheimer’s.

The second is the so-called amyloid hypothesis, which is also a protein believed to create a build-up of plaques in the brain.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches